PRESENTATIONS
Market Access in Australia
Delivered by our Consulting Principal, George Papadopoulos George Papadopoulos | LinkedIn, as part of the Introduction to the Therapeutics Industryprogram at the University of Sydney, this presentation provides a practical overview of Australia’s market access and reimbursement pathways for pharmaceutical and medical technology organisations.
Topics include:
- Health Technology Assessment (HTA)
- The Pharmaceutical Benefits Scheme (PBS)
- The Medical Services Advisory Committee (MSAC)
- The Prescribed List for medical devices
Featuring real-world case studies, this presentation explores the evidence, assessment, and reimbursement processes that enable pharmaceuticals, biotech products, medical devices, and technologies to reach Australian patients.
ARCS 2025 Annual Conference
Session Spotlight: Horizon Scanning and HTA – Past, Present and Future
-
The current lengthy timelines from non-clinical development to implementation continue to hinder timely patient access to innovative therapies.
-
Australia’s current reactive model is no longer sustainable; it’s time for proactive planning.
-
A dedicated, independent body (potentially university-based) to lead structured horizon scanning.
-
Multiple expert committees, each tailored to inform specific use cases such as HTA, national commissioning, and state-based service planning.
-
Federal government funding with integrated coordination across all jurisdictions.
-
Focus on high-impact, budget-significant innovations initially to drive the greatest health and economic benefit.
An IQVIA Business
Contact Us
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries and is dedicated to delivering actionable insights and accelerating innovations. Learn more at www.iqvia.com
ADDRESS
Level 8,141 Walker Street, North Sydney, NSW, 2060
PHONE
GET IN TOUCH
Privacy Policy
Your Privacy Choices